Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $46.67 Average Target Price from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $46.6667.

AVTX has been the subject of several analyst reports. Mizuho upped their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Bank of America began coverage on Avalo Therapeutics in a report on Friday, June 12th. They set a “buy” rating and a $35.00 price objective on the stock. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. BTIG Research reaffirmed a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Finally, HC Wainwright dropped their price objective on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, May 14th.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $18.14 on Thursday. Avalo Therapeutics has a 12 month low of $4.50 and a 12 month high of $24.27. The business has a 50 day simple moving average of $15.75 and a 200-day simple moving average of $16.09. The stock has a market capitalization of $953.78 million, a PE ratio of -3.32 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, equities research analysts anticipate that Avalo Therapeutics will post -2.58 EPS for the current year.

Insider Buying and Selling

In related news, insider Paul Varki sold 75,063 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider owned 3,634 shares of the company’s stock, valued at $73,297.78. This represents a 95.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the transaction, the insider directly owned 3,622 shares in the company, valued at $65,232.22. This represents a 52.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 112,586 shares of company stock valued at $2,089,651 over the last quarter. Company insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Several large investors have recently bought and sold shares of AVTX. Caligan Partners LP acquired a new stake in Avalo Therapeutics in the third quarter valued at $10,592,000. Balyasny Asset Management L.P. acquired a new stake in Avalo Therapeutics in the third quarter valued at $10,390,000. Vanguard Group Inc. grew its holdings in Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after purchasing an additional 525,696 shares during the last quarter. Millennium Management LLC grew its holdings in Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after purchasing an additional 522,548 shares during the last quarter. Finally, Seven Fleet Capital Management LP grew its holdings in Avalo Therapeutics by 806.0% in the first quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after purchasing an additional 510,540 shares during the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.